Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

278
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
278
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

383
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
383
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

13.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents.

American journal of hematology·2026
Same author

Single Antibiotic Use with Ceftriaxone for Prophylaxis of All Open Fractures.

Journal of orthopaedic trauma·2026
Same author

The WFH Guidelines for the Management of Haemophilia: AAV Gene Therapy, 2025.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Characterization of the clinical and laboratory phenotype of hemophilia carriers and trends of utilization of hemostatic therapies: analysis of the American Thrombosis and Hemostasis Network dataset.

Research and practice in thrombosis and haemostasis·2025
Same author

Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies.

Blood advances·2025
Same author

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group.

Haemophilia : the official journal of the World Federation of Hemophilia·2025

Related Experiment Video

Updated: Feb 16, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K

Factor VIII therapy for hemophilia A: current and future issues.

Louis Aledort1, Rolf Ljung, Kenneth Mann

  • 1Mount Sinai School of Medicine, One Gustave L. Levy Place, Box 1006, Newyork, NY, USA.

Expert Review of Hematology
|April 11, 2014
PubMed
Summary

Hemophilia A management involves factor VIII (FVIII) replacement therapy. Key challenges include FVIII immunogenicity, longer-acting products, prophylaxis, and global access to treatment for this bleeding disorder.

Keywords:
FVIIIfactor concentrategene therapygeneticshemophilia Aimmunogenicitylonger-acting FVIIIprophylaxis

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Related Experiment Videos

Last Updated: Feb 16, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.7K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K

Area of Science:

  • Hematology
  • Genetics
  • Pharmacology

Background:

  • Hemophilia A is a congenital, X-linked bleeding disorder.
  • Current management relies on plasma-derived or recombinant factor VIII (FVIII) infusions.

Purpose of the Study:

  • To review current considerations in FVIII replacement therapy for Hemophilia A.
  • To identify major challenges in managing Hemophilia A patients.

Main Methods:

  • Literature review of FVIII replacement therapy.
  • Analysis of current clinical challenges in Hemophilia A management.

Main Results:

  • Primary considerations include FVIII concentrate immunogenicity, longer-acting products, prophylactic use, and product affordability/availability.
  • Major challenges involve increasing FVIII prophylaxis, preventing inhibitors, and expanding global access.

Conclusions:

  • Optimizing Hemophilia A patient outcomes requires addressing FVIII immunogenicity, enhancing prophylaxis, and improving worldwide access to factor concentrates.
  • Future efforts should focus on overcoming these challenges for better Hemophilia A care.